Home » Stocks » CKPT

Checkpoint Therapeutics, Inc. (CKPT)

Stock Price: $3.31 USD -0.03 (-0.81%)
Updated Mar 3, 2021 10:02 AM EST - Market open
Market Cap 231.48M
Revenue (ttm) 1.07M
Net Income (ttm) -21.68M
Shares Out 56.41M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $3.31
Previous Close $3.34
Change ($) -0.03
Change (%) -0.81%
Day's Open 3.40
Day's Range 3.29 - 3.42
Day's Volume 214,090
52-Week Range 1.05 - 5.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

Members include preeminent clinical and scientific thought leaders in oncology Members include preeminent clinical and scientific thought leaders in oncology

GlobeNewsWire - 1 month ago

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that Jame...

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated i...

GlobeNewsWire - 3 months ago

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition...

GlobeNewsWire - 5 months ago

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, toda...

GlobeNewsWire - 5 months ago

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced update...

Benzinga - 5 months ago

Following up on a prior interview on the status of its leading immunotherapy product candidate, cosibelimab, Benzinga spoke with Checkpoint Therapeutics President and CEO James Oliviero about ...

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that Ja...

GlobeNewsWire - 6 months ago

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisiti...

GlobeNewsWire - 7 months ago

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) --  Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that a...

GlobeNewsWire - 10 months ago

- U.S. patent protection through at least May 2038 - Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled

Seeking Alpha - 1 year ago

CKPT expects to submitt a BLA for cosibelimab in 2021.

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that fe...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pri...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...

GlobeNewsWire - 1 year ago

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new ...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisitio...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisitio...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisitio...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisiti...

Zacks Investment Research - 1 year ago

Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

About CKPT

Checkpoint Therapeutics, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a sma... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2017
CEO
James F. Oliviero III, C.F.A., CFA
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
CKPT
Full Company Profile

Financial Performance

In 2019, CKPT's revenue was $1.71 million, a decrease of -51.28% compared to the previous year's $3.51 million. Losses were -$24.71 million, -32.04% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CKPT stock is "Strong Buy." The 12-month stock price forecast is 17.67, which is an increase of 433.35% from the latest price.

Price Target
$17.67
(433.35% upside)
Analyst Consensus: Strong Buy